Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.
about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceNon-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Tailored combination prevention packages and PrEP for young key populations.Gender differences in pharmacokinetics of maintenance dosed buprenorphine.Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label studyEffects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.Methadone, buprenorphine, and street drug interactions with antiretroviral medicationsImportant Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.HIV and adolescents: focus on young key populations.
P2860
Q27692040-3CA2D74B-9F51-4C55-977D-C171DCEBFC4DQ34851665-4B5EA250-3A69-4559-8496-1913F4AE9268Q34952233-D6949E25-FF4A-4DEA-BC9F-41DEF0634DA1Q35061983-69BCB2C9-20BA-4C25-8FDA-AE72ECEFF4BFQ35131207-0C9F48D4-B2D8-4F2B-B4FA-AF5796B30FD0Q35184385-5D07C03C-5E6C-4529-9482-5BB76920B413Q35906594-D5D5D05E-2058-4D41-AB53-CFB0C42D894FQ36105831-66823AD3-8C1D-4D3B-BCA9-34DBDEDDCCD8Q37721776-3396B2AD-2CC3-4159-8EE6-6319B916E1DDQ37763615-DD5C3DA3-E532-4A6A-94AE-49B7E56C22C7Q37962449-CE5F3717-F48B-49F9-9F75-F44620BAA99DQ38093852-AEB3CC8A-84C3-4E02-9E4A-6746CB07EDAEQ38435908-5F3D50C0-5D5A-4167-909B-10C5CA94B0E6Q46119171-51E4651E-98E6-4466-95F4-99DA1C33B1E9
P2860
Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interactions between buprenorp ...... ne, lamivudine, and tenofovir.
@en
Interactions between buprenorp ...... ne, lamivudine, and tenofovir.
@nl
type
label
Interactions between buprenorp ...... ne, lamivudine, and tenofovir.
@en
Interactions between buprenorp ...... ne, lamivudine, and tenofovir.
@nl
prefLabel
Interactions between buprenorp ...... ne, lamivudine, and tenofovir.
@en
Interactions between buprenorp ...... ne, lamivudine, and tenofovir.
@nl
P2093
P2860
P1476
Interactions between buprenorp ...... ine, lamivudine, and tenofovir
@en
P2093
David E Moody
Elinore F McCance-Katz
Gene D Morse
Jennifer Baker
Petrie M Rainey
P2860
P356
10.1111/J.1521-0391.2009.00004.X
P50
P577
2010-01-01T00:00:00Z